Neprilysin Inhibition - A Novel Therapy for Heart Failure.
N Engl J Med. 2014 Aug 30;
Authors: Jessup M
The Food and Drug Administration (FDA) last approved a new oral drug (hydralazine-isosorbide dinitrate) for patients with heart failure and a reduced ejection fraction in 2005 - and this drug was recommended only for self-identified black patients who continued to have symptoms despite evidence-based treatment.(1) The angiotensin-receptor blocker eplerenone was approved for the treatment of heart failure in 2003. (In 2012, the European Medicines Agency approved ivabradine, which has not received FDA approval.) Now, a novel drug, LCZ696, a dual inhibitor of angiotensin II receptor and neprilysin, may prove to be the first disruptive agent to the heart-failure treatment algorithm, . . .
PMID: 25176014 [PubMed - as supplied by publisher]